Activation of Corticotropin-Releasing Factor Receptor 2 Inhibits the Growth of Human Small Cell Lung Carcinoma Cells

REFERENCES

• Fekete, E.M.; Zorrilla, E.P. Physiology, pharmacology, and therapeutic relevance of Urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 2007, 28(1), 1–27.
   PubMed Web of Science ®Google Scholar
• Gravanis, A.; Margioris, A.N. The corticotrophin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications. Curr Med Chem 2005, 12(13), 1503–1512.
   PubMed Web of Science ®Google Scholar
• Bruijnzeel, A.W.; Gold, M.S. The role of corticotrophin-releasing factor peptides in cannabis, nicotine, and alcohol dependence. Brain Res Rev 2005, 49(3), 505–528.
   PubMed Web of Science ®Google Scholar
• Van Pett, K.; Viau, V.; Bittencourt, J.C.; Chan, R.K.; Li, H.Y.; Arias, C.; Prins, G.S.; Perrin, M.; Vale, W.; Sawchenko, P.E. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 2000, 428(2), 191–212.
   PubMed Web of Science ®Google Scholar
• Muramatsu, Y.; Sugino, N.; Suzuki, T.; Totsune, K.; Takahashi, K.; Tashiro, A.; Hongo, M.; Oki, Y.; Sasano, H. Urocortin and corticotrophin-releasing factor receptor expression in normal cycling human ovaries. J Clin Endocrinol Metab 2001, 86(3), 1362–1369.
   PubMed Web of Science ®Google Scholar
• Kimura, Y.; Takahashi, K.; Totsune, K.; Muramatsu, Y.; Kaneko, C.; Darnel, A.D.; Suzuki, T.; Ebina, M.; Nukiwa, T.; Sasano, H. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 2002, 87(1), 340–346.
   PubMed Web of Science ®Google Scholar
• Reubi, J.C.; Waser, B.; Vale, W.; Rivier, J. Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab 2003, 88(7), 3312–3320.
   PubMed Web of Science ®Google Scholar
• lino, K.; Sasano, H.; Oki, Y.; Andoh, N.; Shin, R.W.; Kitamoto, T.; Totsune, K.; Takahashi, K.; Suzuki, H.; Nagura, H.; Yoshimi, T. Urocortin expression in human pituitary gland and pituitary adenoma. J Clin Endocrinol Metab 1997, 82(11), 3842–3850.
   PubMed Web of Science ®Google Scholar
• Arcuri, F.; Cintorino, M.; Florio, P.; Floccari, F.; Pergola, L.; Romagnoli, R.; Petraglia, F.; Tosi, P.; Teresa Del Vecchio, M. Expression of urocortin mRNA and peptide in the human prostate and in prostatic adenocarcinoma. Prostate 2002, 52(3), 167–172.
   PubMed Web of Science ®Google Scholar
• Florio, P.; De Falco, G.; Leucci, E.; Torricelli, M.; Torres, P.B.; Toti, P.; Dell'Anna, A.; Tiso, E.; Santopietro, R.; Leoncini, L.; Petraglia, F. UCN expression is downregulated in human endometrial carcinoma. J Endocrinol 2006, 190(1), 99–105.
   PubMed Web of Science ®Google Scholar
• Wang, J.; Li, S. Corticotropin-releasing factor family and its receptors: tumor therapeutic targets?. Biochem Biophys Res Commun 2007, 362(4), 785–788.
   PubMed Web of Science ®Google Scholar
• Wang, J.; Xu, Y.; Xu, Y.; Zhu, H.; Zhang, R.; Zhang, G.; Li, S. Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest 2008, 26(4), 359–368.
   PubMed Web of Science ®Google Scholar
• Lovenberg, T.W.; Chalmers, D.T.; Liu, C.; De Souza, E.B. CRH2α and CRH2β receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 1995, 136(9), 4139–4142.
   PubMed Web of Science ®Google Scholar
• Wu, Y.; Xu, Y.; Zhou, H.; Tao, J.; Li, S. Expression of urocortin in rat lung and its effect on pulmonary vascular permeability. J Endocrinol 2006, 189(1), 167–178.
   PubMed Web of Science ®Google Scholar
• Wu, Y.; Zhou, H.; Xu, Y.; Li, S. Enhanced expression of urocortin in lung tissues of rats with allergic asthma. Biochem Biophys Res Commun 2006, 341(2), 532–540.
   PubMed Web of Science ®Google Scholar
• Moody, T.W.; Zia, F.; Venugopal, R.; Korman, L.Y.; Goldstein, A.L.; Fagarasan, M. Corticotrophin releasing factor stimulates cyclic AMP, arachidonic acid and growth of lung cancer cell lines. Peptides 1994, 15(2), 281–286.
   PubMed Web of Science ®Google Scholar
• Dieterich, K.D.; Grigoriadis, D.E.; De Souza, E.B. Corticotropin-releasing factor receptors in human small cell lung carcinoma cells: radioligand binding, second messenger, and northern blot analysis data. Endocrinology 1994, 135(4), 1551–1558.
   PubMed Web of Science ®Google Scholar
• Sandler, A.B.; Johnson, D.H.; Herbst, R.S. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 2004, 10(12s4258–s4262. Pt 2.
   PubMed Web of Science ®Google Scholar
• Litz, J.; Sakuntala Warshamana-Greene, G.; Sulanke, G.; Lipson, K.E.; Krystal, G.W. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer 2004, 46(3), 283–291.
   PubMed Web of Science ®Google Scholar
• Sacewicz, M.; Lawnicka, H.; Siejka, A.; Stepieñ, T.; Krupiñski, R.; Komorowski, J.; Stepieñ, H. Inhibition of proliferation, VEGF secretion of human neuroendocrine tumor cell line NCI-H727 by an antagonist of growth hormone-releasing hormone (GH-RH) in vitro. Cancer Lett 2008, 268(1), 120–128.
   PubMed Web of Science ®Google Scholar
• Bale, T.L.; Giordano, F.J.; Hickey, R.P.; Huang, Y.; Nath, A.K.; Peterson, K.L.; Vale, W.W.; Lee, K.F. Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci USA 2002, 99(11), 7734–7739.
   PubMed Web of Science ®Google Scholar
• Morita, Y.; Kaka, T.; Kawazoe, Y.; Fujimoto, M.; Narazaki, M.; Nakagawa, R.; Fukuyama, H.; Nagata, S.; Kishimoto, T. Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor α -induced cell death in fibroblasts. Proc Natl Acad Sci USA 2000, 97(10), 5405–5410.
   PubMed Web of Science ®Google Scholar
• Argilés, J.M.; Figueras, M.; Ametller, E.; Fuster, G.; Olivan, M.; de Oliveira, C.C.; López-Soriano, F.J.; Isfort, R.J.; Busguets, S. Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle Nerve 2008, 37(2), 190–195.
   PubMed Web of Science ®Google Scholar
• Tezval, H.; Jurk, S.; Atschekzei, F.; Serth, J.; Kuczyk, M.A.; Merseburger, A.S. The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways. Prostate 2009, 69(4), 443–448. .
   PubMed Web of Science ®Google Scholar
• Hao, Z.; Huang, Y.; Cleman, J.; Jovin, I.S.; Vale, W.W.; Bale, T.L.; Giordano, F.J. Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc Natl Acad Sci USA 2008, 105(10), 3939–3944.
   PubMed Web of Science ®Google Scholar
• Chanalaris, A.; Lawrence, K.M.; Townsend, P.A.; Davidson, S.; Jamshidi, Y.; Stephanou, A.; Knight, R.D.; Hsu, S.Y.; Hsueh, A.J.; Latchman, D.S. Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway. Biochem Biophys Res Commun 2005, 328(2), 442–448.
   PubMed Web of Science ®Google Scholar
• Valentim, L.; Laurence, K.M.; Townsend, P.A.; Carroll, C.J.; Soond, S.; Scarabelli, T.M.; Knight, R.A.; Latchman, D.S.; Stephanou, A. Urocortin inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed to ischaemia/reperfusion injury. J Mol Cell Cardiol 2006, 40(6), 846–852.
   PubMed Web of Science ®Google Scholar
• Rossant, C.J.; Pinnock, R.D.; Hughes, J.; Hall, M.D.; McNulty, S. Corticotropin-releasing factor type 1 and type 2alpha receptors regulate phosphorylation of calcium/cyclic adenosine 3′,5′-monophosphate response element-binding protein and activation of p42/p44 mitogen-activated protein kinase. Endocrinology 1999, 140(4), 1525–1536.
   PubMed Web of Science ®Google Scholar
• Radulovic, M.; Hippel, C.; Spiess, J. Corticotropin-releasing factor (CRF) rapidly suppresses apoptosis by acting upstream of the activation of caspases. J Neurochem 2003, 84(5), 1074–1085.
   PubMed Web of Science ®Google Scholar
• Tsatsanis, C.; Androulidaki, A.; Dermitzaki, E.; Charalampopoulos, I.; Spiess, J.; Gravanis, A.; Margioris, A.N. Urocortin 1 and Urocortin 2 induce macrophage apoptosis via CRFR2. FEBS Lett 2005, 579(20), 4259–4264.
   PubMed Web of Science ®Google Scholar
• Markovic, D.; Punn, A.; Lehnert, H.; Grammatopoulos, D.K. Intracellular mechanisms regulating corticotropin-releasing hormone receptor-2beta endocytosis and interaction with extracellularly regulated kinase 1/2 and p38 mitogen-activated protein kinase signaling cascades. Mol Endocrinol 2008, 22(3), 689–706.
   PubMed Web of Science ®Google Scholar
• Tsatsanis, C.; Androulidaki, A.; Dermitzaki, E.; Gravanis, A.; Margioris, A.N. Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2. J Cell Physiol 2007, 210(3), 774–783.
   PubMed Web of Science ®Google Scholar
• Jiang, B.H.; Liu, L.Z. AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets 2008, 8(1), 19–26.
   PubMed Web of Science ®Google Scholar
• Tokunaga, E.; Oki, E.; Egashira, A.; Sadanaga, N.; Morita, M.; Kakeji, Y.; Maehara, Y. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008, 8(1), 27–36.
   PubMed Web of Science ®Google Scholar
• Chen, A.; Brar, B.; Choi, C.S.; Rousso, D.; Vaughan, J.; Kuperman, Y.; Kim, S.N.; Donaldson, C.; Smith, S.M.; Jamieson, P.; Li, C.; Nagy, T.R.; Shulman, G.I.; Lee, K.F.; Vale, W. Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc Natl Acad Sci USA 2006, 103(44), 16580–16585.
   PubMed Web of Science ®Google Scholar
• Yoshino, Y.; Aoyagi, M.; Tamaki, M.; Duan, L.; Morimoto, T.; Ohno, K. Activation of p38 MAPK and/or JNK contributes to increased levels of VEGF secretion in human malignant glioma cells. Int J Oncol 2006, 29(4), 981–987.
   PubMed Web of Science ®Google Scholar
• Nakagawa, H.; Matsumiya, T.; Sakaki, H.; Imaizumi, T.; Kubota, K.; Kusumi, A.; Kobayashi, W.; Kimura, H. Expression of vascular endothelial growth factor by photodynamic therapy with mono-L-aspartyl chlorin e6 (NPe6) in oral squamous cell carcinoma. Oral Oncol 2007, 43(6), 544–550.
   PubMed Web of Science ®Google Scholar
• Buteau-Lozano, H.; Velasco, G.; Cristofari, M.; Balaguer, P.; Perrot-Applanat, M. Xenoestrogens modulate vascular endothelial growth factor secretion in breast cancer cells through an estrogen receptor-dependent mechanism. J Endocrinol 2008, 196(2), 399–412.
   PubMed Web of Science ®Google Scholar
• Nie, D.; Krishnamoorthy, S.; Jin, R.; Tang, K.; Chen, Y.; Qiao, Y.; Zacharek, A.; Guo, Y.; Milanini, J.; Pages, G.; Honn, K.V. Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. J Biol Chem 2006, 281(27), 18601–18609.
   PubMed Web of Science ®Google Scholar